All In MedTech

Device Trial Radar · NCT07629206

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

Post Marketing Data Collection on Use of ProSense® Cryoablation System With Adjuvant Endocrine Therapy for the Treatment of Patients With Low-Risk, Early-Stage Breast Cancer (ChoICE Trial)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 17, 2026

Primary completion

Jul 2034

Study completion Sep 2034

Sponsor

Lead sponsor
IceCure Medical Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jun 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality.

Conditions

  • Low-Risk, Early Stage Breast Cancer

Interventions

  • CryoablationDevice

    Cryoablation procedure, without resection, using the IceCure Medical ProSense® Cryoablation System. Patients will be also provided with adjuvant endocrine therapy for 5 years post-treatment. The IceCure ProSense® cryoablation system is intended for cryogenic destruction of tissue by the application of extreme cold temperatures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Ipsilateral Breast Tumor Recurrence (IBTR) RateTime frame: 5 Years
  2. Confirmed and suspected Ipsilateral Breast Tumor Recurrence (IBTR) RateTime frame: 5 Years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Glendale Adventist Medical Center d/b/a Adventist Health Glendale

    Glendale, California · Recruiting

  • Legacy Medical Group-Surgical Oncology at Good Samaritan

    Portland, Oregon · Recruiting

  • The West Clinic, PC dba West Cancer Center

    Germantown, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.